Also see the monthly review of research abstract summaries. To receive a copy of this literature review by email, sign up to receive the Café ICA e-Newsletter.
Researchers from the U of Michigan received $1.8 Million to develop a new therapy for neuropathic pain, which is a condition in which patients experience pain due to damage to a nerve without obvious injury to the tissue.
Read more.
A new funding opportunity announcement (FOA) was released soliciting grant proposals from researchers in the pain field to stimulate and foster a wide range of basic, clinical, and translational studies on pain.
Read more.
At the American Academy of Pain Management’s annual clinical meeting in Phoenix this month, providers learned how to integrate the latest traditional and alternative therapy into their practices.
Read More
On October 15 the FDA held a day-long public workshop to de-mystify the FDA Center for Drug Evaluation and Research’s (CDER) Investigational New Drug (IND) process. Find power point presentations from all presenters and more at the event website.
Read More
The nerve growth factor inhibitor tanezumab is showing great promise for knocking down IC pain. The ICA’s own Medical Advisory Board member, Robert Evans, MD, presented the results of the first proof-of-concept study in IC last week at the 20th Annual Clinical Meeting of the American Academy of Pain Management meeting in Phoenix, Arizona.
Read More
The National Health Council, in partnership with the NIH Office of Extramural Programs, is developing a database that would make information on unfunded but worthwhile NIH research proposals available to the NHC's members and other potential funders of health research.
Site testing will begin in October 2009. Once testing is complete, NIH will notify all non-funded applicants deemed significant and of scientific and technical merit of the availability of the database. The plan is to fully launch the database in January 2010.
Read More
Watson Pharmaceuticals is currently recruiting participants for a clinical trial studying the safety and effectiveness of Uracyst. Women who are 18 years of age and have a diagnosis of IC/PBS may be eligible to participate.
Read More
The first trial of liposomes for IC in actual patients has just been published, taking a giant step forward toward getting a helpful new therapy to you.
Read More
Ever wonder why it seems to take such a long time for new IC medications to become available? Here’s the scoop!
Read More
The NVA awarded Drs. Georgine Lamvu, Denniz Zolnoun and Lori Boardman grants to develop and implement the first-ever Vulvodynia Treatment Registry. Launching in fall 2009, this multi-site registry will allow researchers to study the efficacy of multiple treatments, including, but not limited to, topical medications (eg, lidocaine, gabapentin), oral "pain-blocking" medications (eg, tricyclic antidepressants, anticonvulsants, and muscle relaxants), physical therapy, and surgery. Women receiving medical care at the University of North Carolina, University of Central Florida, and Florida Hospital will be eligible to participate in the Registry.
Read More
TARIS Biomedical, a new pharmaceutical company, announced plans to develop a lidocaine-releasing intravesical system (LiRIS). IC is the first area of focus for LiRIS, which releases a sustained dose of lidocaine (found to decrease IC symptoms for many patients) directly into the bladder. The new device, which is inserted via cystoscope or catheter into the bladder, floats in the urine as the medicine is released across several weeks. The device is removed by conventional, cystoscopically. Scientific advisory staff include leading IC physicians, such as ICA Medical Advisory Board member, Robert Moldwin, MD. For more information, go to http://www.tarisbiomedical.com/ and click on the “Technology” tab to see a snapshot of how the device works.
If you haven’t already taken these two surveys, please do!
-
University of South Florida (USF) nutrition survey: For those of you who gave up before in frustration, USF reports the online survey tool is now working well. USF is asking people with IC, 18 years or older, to participate in the
online survey. The goal of the study is to learn more about the impact of diet on IC. Please allow 15 to 30 minutes to complet e the survey.
-
Experience with standard treatments: Have you wondered whether to have tests and treatments your urologist has recommended for chronic IC symptoms? If you have not yet filled out this
survey it is not too late to do so! Also
review responses from the first 750 patients, many from the United Kingdom. To date about 1,500 people have reported their experience with standard treatments like hydrodistention, instillations, dilation, neuromodulators, surgeries, and 61 prescription drugs. See articles published in the journal
UROLOGY,
National Women's Health Network, and Our Bodies Ourselves
blog.
May, 31 2009 -- May 2009 Cafe ICA
The American College of Obstetricians and Gynecologists (ACOG) 57th Annual Clinical Meeting took place in Chicago in early May, and IC education was on the agenda.
Read More.
Classes at 8 AM are tough enough for most of us, but some 200 urologists got up before dawn to attend Robert Moldwin, MD’s course on IC/Painful Bladder Syndrome (PBS) here at the American Urological Association’s annual meeting.
Read More.
March 31, 2009 -- March 2009 Cafe ICA
University of South Florida is currently recruiting people with IC, age 18 years or older, for an online nutrition study. The goal of the study is to learn more about the impact of diet on IC. Recruitment is currently open. To participate go to the online survey. Please allow 10 minutes to complete the survey.
March 31, 2009 -- March 2009 Cafe ICA
Check out the new website for the Multidisciplinary Approach to Pelvic Pain (MAPP) Research Network, a $37.5 million per year multi-center and multidisciplinary study funded by the National Institutes of Health. The site offers information about research focus areas including epidemiological studies, phenotyping, neuroimaging and neurobiology, and biomarkers. The site will also provide updates on the investigation of the biologic and behavioral relationships between IC/PBS and CP/CPPS and other frequently related symptom-based conditions including fibromyalgia, irritable bowel syndrome (IBS), and chronic fatigue syndrome (CFS). Vulvodynia and migraine headache may also be studied. Visit the new MAPP site at http://www.mappnetwork.org/.
February 28, 2009 -- February 2009 Cafe ICA
The Multidisciplinary Approach to Pelvic Pain (MAPP) Research Network held it’s third meeting on February 3 and 4, 2009, in Santa Monica, California. The network, as National Institutes of Health (NIH) press releases describe, is taking an innovative approach to research. Much of this meeting was devoted to discussing how to manage that innovative process.
Read More
The National Vulvodynia Association (NVA) invites proposals from clinical researchers to develop and then maintain a provider-based Vulvodynia Treatment Registry. This grant requires the participation of at least two researchers from different institutions.
Read More
Archives
Revised November 19, 2009